SR11237

Research use only, not for human use.

SR11237 is a Pan retinoid X receptor (RXR) agonist. SR11237 causes RXR/RXR homodimers to form and transactivate a reporter gene containing a RXR-response element.

SR11237 is a Pan retinoid X receptor (RXR) agonist. SR11237 causes RXR/RXR homodimers to form and transactivate a reporter gene containing a RXR-response element.(In Vitro):SR11237 is effective at transactivating a chloramphenicol acetyltransferase reporter gene through RXRs but not retinoic acid receptors in COS-1 cells.(In Vivo):In Sprague-Dawley rats, SR11237 (BMS-649) (25 mg/kg; i.p.) Caused disturbed ossification and bone morphology in rats, including premature growth plate closure and infiltration of ossified tissue through the central epiphysis.

Using nuclear receptor co-transfection assays in COS-1 cells, that SR11237 is effective at transactivating a chloramphenicol acetyltransferase reporter gene through RXRs but not retinoic acid receptors.

SR11237 (BMS-649) (25 mg/kg; i.p.; daily from post-natal days 5 to 15) causes irregular ossification and premature closure of the growth plate. Animal Model:Sprague-Dawley rats Dosage:25 mg/kg Administration:I.p.; daily from post-natal days 5 to 15 Result:Caused disturbed ossification and bone morphology in rats, including premature growth plate closure and infiltration of ossified tissue through the central epiphysis.

BMS-649

Others

Other Targets

Aurora A

——

——

146670-40-8

380.484

C24H28O4

>98% (HPLC)

In Vitro:?DMSO : 5 mg/mL (13.14 mM)

CC1(C)CCC(C)(C)c2cc(ccc12)C1(OCCO1)c1ccc(cc1)C(O)=O

——

(-20℃)

With Ice Pack

≥ 2 years